STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells
© 2024. The Author(s)..
Antigen-specific T cell receptor-engineered T cell (TCR-T) based immunotherapy has proven to be an effective method to combat cancer. In recent years, cross-talk between the innate and adaptive immune systems may be requisite to optimize sustained antigen-specific immunity, and the stimulator of interferon genes (STING) is a promising therapeutic target for cancer immunotherapy. The level of expression or presentation of antigen in tumor cells affects the recognition and killing of tumor cells by TCR-T. This study aimed at investigating the potential of innate immune stimulation of T cells and engineered T cells to enhance immunotherapy for low-expression antigen cancer cells. We systematically investigated the function and mechanism of cross-talk between STING agonist diABZI and adaptive immune systems. We established NY-ESO-1 full knockout Mel526 cells for this research and found that diABZI activated STING media and TCR signaling pathways. In addition, the results of flow cytometry showed that antigens presentation from cancer cells induced by STING agonist diABZI also improved the affinity of TCR-T cells function against tumor cells in vitro and in vivo. Our findings revealed that diABZI enhanced the immunotherapy efficacy of TCR-T by activating STING media and TCR signaling pathways, improving interferon-γ expression, and increasing antigens presentation of tumor cells. This indicates that STING agonist could be used as a strategy to promote TCR-T cancer immunotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Cell death & disease - 15(2024), 4 vom: 13. Apr., Seite 265 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Ling [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 16.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41419-024-06638-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371043301 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371043301 | ||
| 003 | DE-627 | ||
| 005 | 20240416233037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41419-024-06638-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM371043301 | ||
| 035 | |a (NLM)38615022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Ling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Antigen-specific T cell receptor-engineered T cell (TCR-T) based immunotherapy has proven to be an effective method to combat cancer. In recent years, cross-talk between the innate and adaptive immune systems may be requisite to optimize sustained antigen-specific immunity, and the stimulator of interferon genes (STING) is a promising therapeutic target for cancer immunotherapy. The level of expression or presentation of antigen in tumor cells affects the recognition and killing of tumor cells by TCR-T. This study aimed at investigating the potential of innate immune stimulation of T cells and engineered T cells to enhance immunotherapy for low-expression antigen cancer cells. We systematically investigated the function and mechanism of cross-talk between STING agonist diABZI and adaptive immune systems. We established NY-ESO-1 full knockout Mel526 cells for this research and found that diABZI activated STING media and TCR signaling pathways. In addition, the results of flow cytometry showed that antigens presentation from cancer cells induced by STING agonist diABZI also improved the affinity of TCR-T cells function against tumor cells in vitro and in vivo. Our findings revealed that diABZI enhanced the immunotherapy efficacy of TCR-T by activating STING media and TCR signaling pathways, improving interferon-γ expression, and increasing antigens presentation of tumor cells. This indicates that STING agonist could be used as a strategy to promote TCR-T cancer immunotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 700 | 1 | |a Liang, Zhaoduan |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yunzhuo |e verfasserin |4 aut | |
| 700 | 1 | |a Habimana, Jean de Dieu |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Yuefei |e verfasserin |4 aut | |
| 700 | 1 | |a Amissah, Obed Boadi |e verfasserin |4 aut | |
| 700 | 1 | |a Mukama, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Siqi |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Xuanyan |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Linshuang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Junyi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhaoming |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Rongqi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yinchao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhiyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yirong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell death & disease |d 2010 |g 15(2024), 4 vom: 13. Apr., Seite 265 |w (DE-627)NLM202030881 |x 2041-4889 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:4 |g day:13 |g month:04 |g pages:265 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41419-024-06638-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 4 |b 13 |c 04 |h 265 | ||